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Introduction
In the study of many biological processes, it is often desirable to 
be able to genetically manipulate multiple genes simultaneously. 
A prime example is tumor modeling in mice. The application of 
genomic technologies to the study of cancers has revolutionized our 
understanding of the genetic landscapes of tumors (1, 2); however, 
functional studies are required to make sense of these cataloguing 
efforts to determine how different combinations of the many can-
didate genetic mutations dictate tumor phenotypes and to provide 
accurate models that can be used in preclinical studies to identify 
mutation-specific therapies. Germline genetic manipulation tech-
niques have allowed the generation of lines of mice in which genes 
can be deleted, mutated, silenced, or overexpressed in temporal and 
cell-type–specific manners (3). These approaches have provided 
many insights into cancer development and progression; however, 
the generation of genetically modified mice and their interbreed-
ing to generate compound mutants are time consuming and costly 
processes. In addition, tumor modeling ex vivo using primary cells 
is often complicated by the limited period for which these cells can 
be cultured and the lack of appropriate genetic tools that allow mul-
tiple genetic alterations to be introduced simultaneously into these 
cells. Current gene-delivery approaches aiming to introduce mul-
tiple genetic alterations using plasmid or viral vectors often require 
cumbersome cloning approaches to generate complicated multicis-
tronic vector constructs and/or multiple rounds of transfection or 
transduction and necessitate the introduction of multiple selective 
markers to identify and isolate the appropriate cells.
To address these issues, we have developed the multiple len-
tiviral expression (MuLE) system, which is based on MultiSite 
Gateway cloning (4) and allows the easy and flexible generation of 
polycistronic, replication-incompetent ecotropic or amphotropic 
lentiviruses. This system allows complex combinatorial genetic 
alterations to be introduced into mammalian cells by infection 
ex vivo and in vivo with a single vector. The use of lentiviral gene 
delivery permits the transduction of a wide variety of dividing 
and nondividing cells, and the integration of the provirus into the 
genome provides heritability of the introduced genetic alterations. 
We present examples of cancer engineering ex vivo and in vivo to 
demonstrate that this system, when used alone or in combination 
with germline genetic approaches, provides new experimental 
genetic power in cultured mammalian cells and in mice.
Results
Generation of complex polycistronic lentiviruses using the MuLE vec-
tor toolbox. To be able to quickly and systematically conduct com-
binatorial genetic experiments in cultured mammalian cells and 
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ery vectors. A series of 104 MultiSite Gateway–compatible Entry 
vectors (MuLE Entry vectors, Supplemental Tables 1 and 2; sup-
plemental material available online with this article; doi:10.1172/
JCI79743DS1) that allow several different types of genetic manipu-
lations has been generated. Conventional restriction enzyme clon-
in mouse tissues, we designed a genetic system that allows com-
plex lentiviral gene-delivery vectors to be generated in a very flex-
ible, rapid, and user-friendly manner. We generated a toolbox of 
building-block vectors that allows multiple genetic elements to be 
combinatorially recombined into a family of lentiviral gene-deliv-
Figure 1. Overview of genetic engineering experiments using MuLE vectors. (A) Restriction enzyme cloning is used to generate MuLE Entry vectors with 
a desired genetic insert cloned downstream of a desired promoter (P), with the entire promoter-insert element being surrounded by appropriate attL-attR 
sites. (B) Schematic overview of the MultiSite Gateway–based recombination cloning of 2, 3, or 4 MuLE Entry vectors into lentiviral destination vectors to 
generate multicistronic MuLE lentiviral expression vectors. The specific attL-attR sites that mediate each recombination are depicted. CMR, chlorampheni-
col resistance gene; ccdB, ccdB toxin gene. (C) Transfection of 293T cells with a MuLE expression vector plasmid together with a lentiviral packaging vector 
(psPAX2) and a vector encoding either amphotropic (MD2G) or ecotropic (pEco) envelope proteins generates MuLE lentiviruses for transduction of cultured 
cells or for in vivo injection into mouse tissues.
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ous recombination reactions with the MuLE system and found 
that approximately 90%, 65%, or 25% of all bacterial colonies 
isolated from recombinations involving 2, 3, or 4 Entry vectors, 
respectively, contained the desired product (Figure 2J). Thus, 
highly complicated, multicistronic MuLE expression vectors can 
be easily cloned. These complex vectors can be stably replicated 
in bacteria and show no evidence of unwanted genetic recombi-
nation (Supplemental Figure 1). Similarly to all lentiviral vectors, 
there is an inverse relationship between the size of the MuLE 
provirus and the titer of the generated virus, with proviruses up 
to 7.5 kb yielding titers of approximately 106 CFU/ml and very 
large (12.5 kb) proviruses yielding titers of approximately 103 
CFU/ml (Supplemental Figure 2). All of these vectors have been 
deposited with Addgene and can be obtained individually or as 
a 96-vector set. Addgene reference numbers for each vector are 
provided in Supplemental Tables 1 and 2.
While the MuLE system is compatible with the VSV-G 
amphotropic envelope protein (Supplemental Figure 5 shows an 
example), for biosafety reasons, all lentiviruses used to transduce 
murine cells in this study were pseudotyped with an ecotropic 
envelope protein from the Moloney murine leukemia virus that 
has been described as allowing lentiviral infection of murine 
fibroblast and hematopoietic cells, but not of human cells (7, 8). 
Despite obvious biosafety advantages, this envelope has surpris-
ingly found very little use in research laboratories. We further 
examined the cellular tropism of MuLE lentiviruses pseudotyped 
with this envelope and found that they infect a variety of cultured 
primary cells, including mouse embryonic fibroblasts (MEFs), 
embryonic stem cells, kidney epithelial cells, endometrial epi-
thelial cells, hepatocytes, and aortic endothelial cells as well as 
immortalized myoblast, melanoma, lung carcinoma, and colorec-
tal carcinoma cell lines, but were not able to infect several human 
cell lines, including 786-O, 293T (Figure 3A), HeLa, and MCF-7 
(data not shown). Cell-type–specific gene expression is also pos-
sible using MuLE vectors. Cloning EGFP downstream of the renal 
epithelium–specific Ksp1.3 promoter in a MuLE vector (Figure 
3B) allowed expression of EGFP in renal epithelial cells but not 
in MEFs (Figure 3C). Thus, ecotropic MuLE viruses can infect a 
broad spectrum of target cells and can be utilized to induce gene 
expression in a cell-type–specific manner.
In order to validate the functionality of the vector toolbox for 
the genetic manipulation of primary cells, we conducted a series of 
experiments involving transduction of primary MEFs. Unless oth-
erwise stated, all experiments in this publication were conducted 
at an MOI of 1. These validation studies demonstrated that MuLE 
vectors are capable of the following: (a) inducing shRNA-mediated 
knockdown from different pol III promoters (Supplemental Figure 
3, A–C); (b) inducing simultaneous double-gene knockdowns from 
a single vector in a manner in which the strengths of the knock-
downs are independent of the order of the knockdown cassettes 
in the vector (Supplemental Figure 3, D and E) and are equivalent 
to the extent of knockdowns obtained from vectors expressing 
the single shRNAs (Supplemental Figure 3, F and G); (c) induc-
ing sh RNA–miR-30–mediated constitutive (Supplemental Figure 
3, H–J) and inducible (Supplemental Figure 3, K–M) gene knock-
down; (d) inducing tamoxifen-inducible Cre-ERT2–mediated gene 
deletion (Supplemental Figure 4, A and B); and (e) inducing the 
ing is first used to clone genetic inserts downstream of a promoter 
of choice, with the entire promoter-insert genetic element being 
flanked by specific attL and attR sites (Figure 1A). MuLE Entry 
vectors can be recombined efficiently in an overnight reaction via 
an attL-attR recombination with a variety of Gateway destination 
lentiviral vectors that we have generated. The choice of different 
attL-attR sites provides directional specificity to the recombina-
tion reactions and allows either 1, 2, 3, or 4 MuLE Entry vectors to 
be simultaneously recombined into the Destination vector. Using 
this system, complex multicistronic mammalian expression vec-
tors containing 2, 3, 4, or 5 independent genetic elements can be 
rapidly generated (Figure 1B). MuLE vectors can be packaged to 
generate amphotropic or ecotropic lentiviruses, which can then 
be used for infection of cultured cell lines, primary cells ex vivo 
or cells in mouse tissues in vivo (Figure 1C). This entire procedure 
can be completed within 7 to 8 days.
We generated Entry vectors containing 3 different RNA poly-
merase (pol) II promoters (CMV, SV40, SFFV) and a multiple 
cloning site (MCS) to generate genetic elements allowing consti-
tutive cDNA overexpression (Figure 2A). An Entry vector with a 
CMV promoter and loxP sites flanking the MCS allows for Cre-
mediated conditional removal of inserted genes (Figure 2A) and 
Entry vectors containing a doxycycline-inducible (DOX-induc-
ible) CMV/TO promoter allow inducible gene expression (Figure 
2B). Supplemental Table 3 shows the restriction enzyme sites of 
the MCS of each vector. Promoterless Entry vectors containing 
only a MCS flanked by different combinations of attL-attR sites 
(Figure 2C) represent flexible elements that facilitate the gen-
eration of diverse types of complex vector constructs. We gen-
erated Entry vectors to allow U6 promoter–driven expression of 
short guide RNAs (sgRNAs) for CRISPR/Cas9-mediated (where 
CRISPR indicates clustered regularly interspaced short palin-
dromic repeats) gene mutation (Figure 2D). Entry vectors with 3 
different constitutive pol III promoters (U6, 7SK, H1) allowed the 
expression of shRNAs (Figure 2E). For constitutive expression of 
shRNAs in microRNA-30 (miR-30) format, we generated Entry 
vectors based on the pSM2 plasmid (5), which includes the 5′ and 
3′ flanking sequences from miR-30 driven by the U6, 7SK, or H1 
pol III promoters (Figure 2F). A DOX-inducible gene knockdown 
vector was generated by using the CMV/TO promoter to drive 
shRNA–miR-30 expression (Figure 2G). In addition to these flex-
ible cloning vectors, we created several ready-to-use Entry vec-
tors containing cDNAs for hCas9, fluorescent proteins (EGFP, 
mCherry, near-infrared fluorescent protein [iRFP], tdTomato), 
enzymatic reporters (luciferase, lacZ), drug resistance (puro-
mycin), and tamoxifen-inducible Cre recombinase (Cre-ERT2) 
(Figure 2H). To allow a high degree of flexibility in combining 
different numbers and types of Entry vectors by recombination 
cloning, most of the described vectors are available with multiple 
combinations of different attL-attR sites (Supplemental Tables 1 
and 2). We further extended our vector toolbox by generating a 
series of lentiviral Destination vectors based on modifications of 
the previously described pLenti X1-Puro-DEST vector (6), allow-
ing cells to be marked with drug resistance (puromycin, neomy-
cin) or a variety of fluorescent (EGFP, iRFP, IFP1.4) or lumines-
cent (luciferase) proteins (Figure 2I) to facilitate cellular assays 
as well as live animal-imaging studies. We performed numer-
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Engineering genetically complex tumors from primary cells using 
single MuLE viruses. To demonstrate the utility of the MuLE system 
in cancer modeling, we performed experiments in MEFs show-
ing that a single virus can reproduce several phenotypes that are 
known to result from genetic cooperation between oncogenes and 
tumor-suppressor genes. Overexpression of an oncogenic form of 
simultaneous expression of 2 shRNAs, 2 cDNAs, and a drug-resis-
tance gene from 5 different expression cassettes in a single vec-
tor (Supplemental Figure 4, C–E). Transduction of human A-375 
melanoma cells showed that MuLE viruses expressing iRFP or 
luciferase proteins allow quantitative monitoring of tumor burden 
in xenograft experiments (Supplemental Figure 5).
Figure 2. The MuLE vector toolbox. (A and B) MuLE Entry vectors for pol II promoter–driven constitutive expression (A) or DOX-inducible expression (B). 
(C) Promoterless MuLE Entry vectors. (D) MuLE Entry vectors for U6-driven expression of sgRNAs. (E and F) MuLE Entry vectors for shRNA-based (E) and 
shRNA–miR-30–based (F) gene knockdown using pol III promoters and (G) a DOX-inducible miR-30–based shRNA expression vector. Restriction enzyme 
sites for cloning are shown. (H) Schematic representation of MuLE Entry vectors for expression of hCas9, fluorescent proteins (EGFP, mCherry, iRFP, 
td Tomato), firefly-luciferase, β-galactosidase (LacZ), puromycin resistance, or Cre-ERT2. P, various promoters. In all panels, attA and attB denote that mul-
tiple combinations of MultiSite Gateway attL-attR sites are available for these vectors. (I) Schematic representation of Destination vectors modified from 
the pLenti X1 series to contain the different expression cassettes shown. (J) Quantification (mean ± SD) of recombination efficiencies of n independent 
MultiSite Gateway attL-attR recombinations using 2, 3, or 4 MuLE Entry vectors.
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upon induction with DOX (Figure 5B). These cells grew efficiently 
as tumors when injected subcutaneously in immunocompromised 
SCID/beige mice only upon addition of DOX to the drinking water 
(Figure 5, C–E), demonstrating that MuLE vectors can be employed 
to generate regulatable and quantitatively monitorable models of 
cancer based on cooperative genetic interactions.
To further demonstrate the potential of MuLE vectors for 
engineering and monitoring genetically complex tumors, we gen-
erated a pentacistronic vector to simultaneously express sh RNA–
miR-30 against the Retinoblastoma (Rb1) tumor-suppressor gene 
and shRNA against the phosphatase and tensin homolog (Pten) 
tumor-suppressor gene as well as to express oncogenic H-RasG12V, 
Cre-ERT2, and the puromycin resistance gene (Figure 6A). We 
transduced (MOI = 2) primary MEFs harboring floxed alleles of 
the von Hippel–Lindau (Vhl) and Trp53 genes (Vhlfl/fl Trp53fl/fl) and 
treated puromycin-selected cells with 300 nM 4-hydroxytamox-
ifen (4-OHT) or vehicle for a period of 3 days. Cells transduced 
with the lentivirus and treated with 4-OHT showed reduction of 
VHL abundance (accompanied by stabilization of HIF1A), reduc-
tion of PTEN, pRb, and p53 protein levels, and overexpression of 
H-RasG12V, (Figure 6B) thus demonstrating the functionality of each 
expression cassette in the MuLE vector. To analyze the potential of 
these cells to form genetically defined tumors in vivo, we addition-
ally transduced the cells with a MuLE virus expressing EGFP and 
iRFP, thereby generating within 1 week pools of cells that harbored 
5 separate genetic changes and expression of 3 marker genes. Cells 
that were treated with 4-OHT grew marginally faster in xenograft 
H-Ras (G12V) in combination with loss of function of p53 results 
in cellular transformation (9, 10). We generated a tricistronic 
lentiviral expression vector designed to simultaneously express 
sh RNA–miR-30 against transformation-related protein 53 (Trp53) 
and express oncogenic H-RasG12V and puromycin resistance (Figure 
4A) as well as control viruses expressing neither or only 1 of these 
elements. Western blot analysis of puromycin-selected primary 
MEFs demonstrated the expected knockdown of p53 and overex-
pression of H-RasG12V (Figure 4B), and transformation assays dem-
onstrated that Trp53 knockdown alone allowed colony formation 
following plating at low density (Figure 4C), but that loss of contact 
inhibition (foci formation) and anchorage-independent growth 
occurred only in cells with simultaneous knockdown of Trp53 and 
overexpression of H-RasG12V, as expected (Figure 4, D–F). Similar-
ly, the use of a single MuLE vector to simultaneously knock down 
Trp53 and overexpress Myc (Figure 4, G and H) allowed growth of 
cells at low density (Figure 4I) and reproduced the known effect of 
loss of Trp53 function in rescuing Myc-induced apoptosis in MEFs 
(ref. 11 and Figure 4J).
To further prove the utility of our system in tumor modeling, 
we generated a multicistronic vector designed to knock down 
Trp53, overexpress H-RasG12V from the inducible CMV/TO promot-
er, and express iRFP to allow monitoring of tumor development 
(Figure 5A). Blasticidin-resistant MEFs after infection with pLenti-
CMV-TetR-Blast (6) were transduced with the MuLE vector and 
selected with puromycin. Western blot analysis indicated constitu-
tive p53 knockdown, but H-RasG12V overexpression occurred only 
Figure 3. Broad cellular tropism and cell-type–specific expression of 
ecotropic MuLE vectors. (A) Luminescent imaging of various human and 
mouse cultured cells after infection with ecotropic MuLE viruses expressing 
an empty cassette (Ctrl) or luciferase (Luc). The human kidney cell lines 293T 
and 786-0 were not infected by these viruses, but various primary mouse 
cells and cell lines were infected, including MEFs, embryonic stem cells (ES), 
kidney epithelial cells (KEC), endometrial epithelial cells (EEC), aortic endo-
thelial cells (AEC), hepatocytes (Hep), myoblasts (C2C12), melanoma cells 
(B16), lung carcinoma cells (LLC-1), and colorectal carcinoma cells (MC-38). 
(B) Schematic of MuLE vectors with or without the kidney epithelium–spe-
cific Ksp1.3 promoter cloned upstream of a cDNA encoding EGFP. (C) Repre-
sentative bright field (BF) and green fluorescence (EGFP) images of primary 
mouse kidney epithelial cells (PKCs) and primary MEFs transduced with the 
lentiviral vectors shown in B. Original magnification, ×1 (A); ×10 (C).
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assays than those that were not treated (Figure 6C and Supple-
mental Figure 6, A and B). Importantly, cells that were isolated 
from the tumors 3 weeks after injection retained EGFP expres-
sion (data not shown) and displayed the same changes in protein 
abundance that were present in the cells before injection (Figure 
6D), demonstrating that MuLE viruses permit the introduction of 
stable genetic alterations.
We took advantage of this system to perform proof-of-prin-
ciple therapeutic target identification experiments to show that 
MuLE viruses can be employed to assess which genes are neces-
sary for the growth of tumors with a defined set of genetic muta-
tions. Using the same work flow described above, we infected pri-
mary MEFs derived from WT, Hif1afl/fl, Hif2afl/fl, or Hif1afl/fl Hif2afl/fl 
mice with the virus shown in Figure 6A to assess the contribution 
of the hypoxia-inducible factor α (HIF1α and HIF2α) transcription 
factors to tumor development in the background of oncogenic 
H-RasG12V together with loss of function of Rb1 and Pten. mRNA 
analyses confirmed that 4-OHT treatment induced the antici-
pated downregulation of Hif1a and/or Hif2a and of several Hif1a 
target genes in these cells (Figure 7A). Xenograft experiments 
revealed that HIF1α, but not HIF2α, is necessary for efficient 
tumor growth in this model (Figure 7, B–E). All tumors described 
in Figures 6 and 7 displayed a similar histological appearance of 
sarcomatoid cells growing in a storiform pattern, with numerous 
tumor giant cells with bizarre nuclei (Supplemental Figure 6, C 
and D). We took advantage of this large set of imaging data to per-
form an analysis of the utility of iRFP to monitor tumor growth. 
iRFP is a new fluorescent protein that has been proposed to be 
Figure 4. Combinatorial genetics using MuLE vectors. (A) Lentiviral vector to simultaneously knock down Trp53 and overexpress oncogenic H-RasG12V. (B) 
Western blot analysis of primary MEFs transduced with the indicated lentiviruses. (C) Crystal violet staining of the same cells 14 days after seeding at low den-
sity and (D) 14 days after seeding in a focus formation assay. (E) Representative images of the same cells seeded in a soft agar colony assay after 3 weeks of 
growth. Scale bars: 200 μm. (F) Quantification of the foci and colonies growing in assays from D and E. (G) Lentiviral vector generated to simultaneously knock 
down Trp53 and overexpress Myc. (H) Western blot analysis of primary MEFs transduced with the indicated lentiviruses. (I) Crystal violet staining of the same 
cells 14 days after seeding at low density. (J) Quantification of viable cells 3 days after transduction with the indicated lentiviruses. All graphs depict mean ± 
SD. Student’s t test, n = 3. **P < 0.01; ***P < 0.001.
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excellent for animal imaging due to the low absorbance by mouse 
tissues of the emitted light (12–14). In each of the 5 experiments 
described above, there was a strong linear correlation between the 
iRFP signal and the measured tumor volume over time, with Pear-
son correlation coefficient R2 values ranging from 0.79 to 0.94 in 
the experiments (Supplemental Figure 6E), supporting the utility 
of iRFP as an excellent marker protein to track tumor formation 
and progression in mouse imaging studies.
Combinatorial CRISPR/Cas9-mediated genetic engineering 
using single MuLE vectors. The discovery of the applicability of the 
CRISPR/Cas9 system to mammalian cells has provided a power-
ful new tool to efficiently target genetic mutations to defined loci 
(15, 16), and very recent publications illustrate the power of this 
system for tumor engineering in mice (17–20). We reasoned that 
the ease and flexibility of cloning provided by the MuLE system 
would make it an ideal experimental platform to generate vec-
tors that allow the introduction of multiple simultaneous genetic 
manipulations using CRISPR/Cas9. We first generated tricistronic 
MuLE vectors expressing single sgRNAs targeting exon 7 or exon 8 
of the Trp53 locus or exon 2 of the cyclin-dependent kinase inhibi-
tor 2A (Cdkn2a) locus together with expression of hCas9 and puro-
mycin resistance (Supplemental Figure 7A) and infected primary 
MEFs. Two functionally validated Trp53 sgRNAs (21) and 3 newly 
designed Cdkn2a sgRNAs, but not a scrambled control sgRNA 
(21), induced efficient mutation of their respective target genes, as 
shown by Surveyor assays (Supplemental Figure 7B). Both Trp53 
sgRNAs caused the generation of truncated p53 protein species, 
and 2 of 3 Cdkn2a sgRNAs caused loss of p16 and p19 protein 
expression (Supplemental Figure 7C), verifying that CRISPR/
Cas9 genome engineering is compatible with the MuLE system.
To demonstrate that cooperative genetic tumor modeling 
can be achieved using CRISPR/Cas9-mediated gene knockout 
together with oncogene overexpression from a single vector, we 
generated tetracistronic MuLE vectors designed to express either 
scrambled sgRNA or sgRNAs targeting Trp53 exon 7 or exon 8 as 
well as to express H-RasG12V, hCas9, and puromycin resistance (Fig-
ure 8A) and used these to infect primary MEFs. All viruses express-
ing sgRNA against Trp53, but not the control virus, allowed colony 
formation following plating of cells at low density (Figure 8B), but 
tumor formation in xenograft assays only resulted from the com-
bination of sgRNA against Trp53 with H-RasG12V expression (Figure 
8C). Western blotting of independent cell lines isolated from inde-
pendent tumor xenografts of each genotype confirmed the over-
expression of H-RasG12V and the presence of numerous truncated 
mutant p53 protein species (Figure 8D).
Previous approaches using the CRISPR/Cas9 system to gener-
ate cells harboring multiple mutations required the cotransfection 
of multiple plasmids, the simultaneous infection with multiple 
viruses, and the use of transgenic mice that express hCas9 or that 
carry germline floxed alleles (17, 18, 20, 22, 23). The multicistronic 
building-block MuLE viral system allows multiple sgRNAs to be 
expressed together with hCas9 from a single viral construct. To 
prove that this approach of targeting multiple loci simultaneously 
with a single vector is feasible, we generated pentacistronic MuLE 
viruses, each simultaneously expressing sgRNAs against the 
Trp53, Pten, and Vhl tumor-suppressor genes, hCas9, and puromy-
cin resistance (Figure 8E). Two different sgRNAs targeting Trp53 
exon 7 or exon 8, 3 different sgRNAs targeting Pten exon 1 or exon 
2, and 3 different sgRNAs targeting Vhl exon 1 were combined 
to generate 3 independent MuLE viruses expressing different 
sets of sgRNAs. After infection and selection for drug resistance, 
cells were plated at low density to assess cellular transformation. 
All viruses allowed the formation of colonies (Figure 8F), indica-
tive of loss of p53 function, and a total of 21 clonal immortalized 
cell lines were derived from isolated colonies. Western blotting 
revealed the complete loss or reduction of expression of PTEN 
and VHL and presence of truncated p53 protein species in 16, 14, 
and 20 clones, respectively (Figure 8G). All clones displayed levels 
Figure 5. Combinatorial genetics using inducible MuLE vectors. (A) Multicistronic lentiviral vector to simultaneously knock down Trp53, overexpress 
inducible H-RasG12V, and overexpress iRFP. (B) Western blot analysis demonstrating H-RasG12V overexpression in TetR-expressing MEFs transduced with the 
lentivirus shown in A upon addition of 1 μM DOX to the culture medium. (C) In vivo fluorescence imaging of mice that were subcutaneously injected with 
shRNA-Trp53/CMV/TO-H-RasG12V MuLE virus–infected MEFs and fed drinking water without or with DOX. (D) Longitudinal tumor growth quantified by iRFP 
fluorescence imaging. (E) Image of the isolated tumors and tumor weight after 28 days. Scale bar: 1 cm. Student’s t test, n = 3. *P < 0.05; **P < 0.01.
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together with H-RasG12V and EGFP. These MuLE vectors and con-
trol vectors expressing either nonsilencing shRNA, the shRNA X 
library alone, or H-RasG12V alone were transduced into MEFs at an 
MOI of 0.1 to avoid multiple integrations into the same cell. Trans-
duced cells were plated at low density in the presence of a 30-fold 
excess of WT MEFs for a focus formation assay. The combination 
of the shRNA X library plus H-RasG12V resulted in an increased 
number of foci (Figure 9B). Eight EGFP-positive foci were isolat-
ed and expanded as cell lines. PCR followed by DNA sequencing 
was used to isolate and identify the integrated shRNA, revealing 
that 7 of these clones contained shRNA against Cdkn2a (clone 
TRCN0000222731) and 1 contained shRNA against Trp53 (clone 
TRCN0000012360). Western blotting verified the knockdown of 
p19 and p16 protein expression in the Cdkn2a shRNA–expressing 
cell lines and of p53 in the Trp53 shRNA–expressing cell line (Fig-
ure 9C). Reengineering MuLE viruses to express the isolated Cdk-
n2a shRNA together with H-RasG12V and iRFP expression cassettes, 
as well as relevant control viruses, confirmed that this genetic 
cooperation causes transformation of MEFs and allows these cells 
to grow as xenografts in immunocompromised mice (Figure 9, D 
and E). Loss of function of Cdkn2a or of Trp53 has been shown 
to cooperate with activated H-Ras in causing transformation of 
MEFs (24), validating the effectiveness of screening for coopera-
tive genetic events with the MuLE system.
Generation of genetically complex, quantitatively monitorable 
autochthonous sarcomas in mice using single MuLE viruses. Hav-
ing established the power of the MuLE system for combinatorial 
genetics in primary cells ex vivo and based on experiments show-
of the p53-inducible p21 protein equivalent to levels in Vhl/Trp53 
null MEFs, verifying that functional p53 knockout occurred in all 
clones. Sixteen clones displayed stabilization of HIF1α protein, 
and 14 clones displayed elevated levels of P-S473-Akt, indicative 
of functional loss of VHL and PTEN, respectively (Figure 8G). 
Since some clones retained protein expression of p53, VHL, and/
or PTEN, we further validated that mutations arose at all loci by 
using deep sequencing to genotype the regions of Pten, Trp53, and 
Vhl targeted by the sgRNAs in each of 10 clones (Table 1). Half 
of the clones showed insertions or deletions of all 6 alleles, and 
half showed mutations of 5 of 6 alleles, demonstrating that infec-
tion with a single MuLE CRISPR/Cas9 vector can simultaneously 
induce mutations in multiple target genes.
Combinatorial genetic screening using MuLE vectors. Another 
advantage of the building-block nature of the MuLE system is 
that it provides a platform to facilitate population-based genetic 
interaction screens. As proof of principle that this is feasible, we 
conducted a screen to identify negative regulators of the cell cycle 
whose loss of function can cooperate with H-RasG12V to allow trans-
formation of MEFs. We assembled an shRNA library (designated 
shRNA X) in the commercially available pLKO.1 vector backbone, 
comprising 4 to 6 shRNAs against each member of the Cdkn1, 
Cdkn2, Trp53, and Rb gene families (Figure 9A). PCR was used 
to amplify all shRNAs, including the U6 promoter, from a pooled 
DNA preparation of this library, and the product was cloned en 
masse into a MuLE Entry vector to generate an Entry shRNA X 
library, which was recombined to generate a library of tricistronic 
MuLE vectors, each expressing a single shRNA from the library 
Figure 6. Generation of genetically complex tumors with multicistronic MuLE vectors. (A) Pentacistronic vector to simultaneously knock down Rb1 and Pten 
and to express CreERT2, oncogenic H-RasG12V, and puromycin resistance. (B) Western blot analysis of puromycin-selected Vhlfl/fl Trp53fl/fl primary MEFs that were 
transduced with lentivirus shown in A, virus containing 4 empty inserts (Ctrl), or 3 empty inserts plus CreERT2, and treated with 300 nM 4-OHT or ethanol (EtOH) 
for 4 days. (C) In vivo fluorescence images of mice taken 2 and 21 days after subcutaneous injection of Vhlfl/fl Trp53fl/fl MEFs transduced with lentivirus generated 
from the vector shown in A that had been treated with EtOH (left flank) or with 4-OHT (right flank) prior to injection. (D) Western blot analysis of tumor cells 
that were isolated from 3 separate tumors of each genotype 3 weeks after cell injection.
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the HRAS, KRAS, or NRAS genes or homozygous deletions of NF1 
(31–35). Some RMS tumors also harbor loss-of-function muta-
tions or gene deletions in the CDKN2A, TP53, and PTEN genes 
(32–34, 36, 37), and systematic analysis of the status of the TP53 
and CDKN2A loci, as well as of their respective proteins, revealed 
that UPS tumors almost universally display loss of 1 or more com-
ponents of the p53 pathway (38). To determine whether MuLE 
viruses could be utilized to model human sarcomas, we gener-
ated a series of MuLE vectors designed to systematically investi-
gate the single and combinatorial effects of gain of H-Ras function 
and loss of Cdkn2a, Trp53, and Pten functions. All MuLE vectors 
expressed luciferase to mark infected cells, allowing quantita-
tive monitoring of tumor development. Concentrated ecotropic 
lentiviruses (107 CFU/ml) were injected once into each gastroc-
nemius muscle of 18-day-old SCID/beige immunocompromised 
mice. Injection of empty control virus, viruses expressing only 
ing that combinatorial genetic manipulations via lentiviral injec-
tion can generate brain tumors (25), we tested whether autochtho-
nous tumors could also be induced in mice via direct transduction 
of cells with MuLE viruses in vivo. Using R26-lox-STOP-lox-td-
Tomato mice (26) as a reporter system to monitor cellular infec-
tion, we found that injection of ecotropic viruses expressing Cre 
into the gastrocnemius muscle of mice induced tdTomato fluo-
rescence in muscle fibers and small cells adjacent to muscle fibers 
(Figure 10A). Mouse models have demonstrated that oncogenic 
K-Ras expression combined with loss of Trp53 or Cdkn2a func-
tion in skeletal muscle cells of different stages of differentiation 
causes several types of soft tissue sarcomas, including embryonal 
and pleomorphic rhabdomyosarcomas (RMS) as well as undiffer-
entiated pleomorphic sarcomas (UPS) with or without myogenic 
differentiation (27–30). The RAS-signaling pathway is frequently 
activated in childhood RMS tumors due to oncogenic mutations in 
Figure 7. Hif1a but not Hif2a is necessary for efficient growth of Pten/Rb1-deficient, H-RasG12V–expressing tumors. (A) mRNA expression analysis of the 
indicated genes in WT, Hif1afl/fl, Hif2afl/fl, and Hif1afl/fl Hif2afl/fl MEFs that were transduced with lentivirus generated from the vector shown in Figure 6A 96 
hours after induction of CreERT2 with 300 nm 4-OHT. Shown are ratios of 4-OHT treated to EtOH treated. (B–E) In vivo fluorescence imaging at the day of 
euthanasia (top left panels), excised tumors (top right panels), and longitudinal tumor growth (bottom panels) of mice injected with cells described in A 
that had been treated with EtOH (left flank) or 4-OHT (right flank) prior to subcutaneous injection. Color intensity in B–E is the same as in Figure 6C. Scale 
bars: 1 cm. All graphs depict mean ± SD. Student’s t test, n = 3–6. *P < 0.05; **P < 0.01.
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NA-Cdkn2a plus H-RasG12V (n = 16), shRNA-Trp53 plus H-RasG12V 
(n = 8), and shRNA-Trp53 plus shRNA-Pten plus H-RasG12V (n = 6) 
combinatorial viruses as early as 10 days after injection (Figure 
10, B and C). These signals increased over time, and all mice 
developed large tumors at the site of injection (Figure 10, D and 
E), requiring euthanasia of the animals 4 to 8 weeks after injec-
H-RasG12V, only sh RNA-Cdkn2a, shRNA-Trp53, or shRNA-Pten, 
or viruses expressing shRNA-Trp53 plus shRNA-Pten or shRNA-
Pten plus H-RasG12V did not cause any large increases in luciferase 
signal over time (Figure 10, B and C), and no tumors developed 
within 4 months of injection. However, large increases in lucifer-
ase signal were evident in all muscles that were injected with shR-
Figure 8. Combinatorial genetics using the CRISPR/Cas9 system in MuLE vectors. (A) Schematic of MuLE vector expressing sgRNA against Trp53 and 
expressing H-RasG12V, hCas9, and puromycin resistance. (B) MEFs were infected with the indicated viruses expressing sgRNAs targeting Trp53 exon 7 (Ex7) 
or exon 8 with or without H-RasG12V expression, plated at low density 6 days after transduction, and stained with crystal violet 14 days after plating. (C) 
Growth of cells as tumor xenografts and images of tumors derived from the combination of Trp53 exon 7 or exon 8 sgRNAs with H-RasG12V overexpression. 
(D) Western blot analysis of tumor cells that were isolated from 3 separate tumors of each genotype 5 weeks after cell injection. (E) Schematic of MuLE 
vector simultaneously expressing sgRNAs against Trp53, Pten, and Vhl and expressing hCas9 and puromycin resistance. (F) MEFs infected with 3 inde-
pendent combinations of different sgRNAs formed colonies when plated at low density 10 days after viral transduction. (G) Western blotting of cell lines 
(lanes 1–21) derived from colonies that formed after infection with viruses expressing the indicated combinations of sgRNAs.
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Discussion
We show proof-of-principle examples that illustrate the user 
friendliness, speed, versatility, and genetic power of the MuLE 
system in primary mammalian cells. Complex genetic modula-
tions involving combinatorial gene overexpression, knockdown, 
and knockout can be achieved using single viral infections. The 
simultaneous marking of infected cells with a variety of reporter 
cassettes facilitates cellular studies and in vivo imaging stud-
ies. By expressing multiple sgRNAs together with hCas9, single 
MuLE vectors are able to simultaneously target genetic mutations 
to multiple loci, providing a platform that harnesses the genetic 
power of the CRISPR/Cas9 system for performing combinatorial 
genetic manipulations. Combinatorial genetic screening experi-
ments are also possible by combining libraries of Entry vectors 
with Entry vectors that encode defined genetic alterations. The 
ease of combining different genetic elements using this system 
represents a tool that will greatly facilitate systematic combina-
torial genetic studies in mammalian cells. Although this study 
focuses on tumor biology, the MuLE system will be widely appli-
cable to numerous areas of biological investigation. It is hoped 
that other investigators will utilize the building-block nature of 
the system to generate new Entry vectors that will expand the 
range of possible genetic manipulations.
While there are several theoretical concerns that could 
potentially be envisaged as limiting the utility of complex MuLE 
lentiviruses, our data indicate that these do not represent signifi-
cant problems. While some lentiviral vector plasmids are unsta-
ble in bacteria, MuLE vector plasmids are not prone to unwanted 
recombination during bacterial propagation. Another potential 
source of recombination in lentiviral vectors is at the level of 
tion. Histological analysis of the tumors revealed that they were 
undifferentiated sarcomas with pleomorphic and rhabdoid fea-
tures. Tumors contained undifferentiated round to spindle cells 
and an admixture of polygonal cells with densely eosinophilic 
cytoplasm in spindle, tadpole, and racquet-like contours (Figure 
10, F–K). The presence of pleomorphic polygonal rhabdoid cells 
(Figure 10, G, I, and K) and the demonstration by electron micros-
copy of rudimentary sarcomere formation in the malignant cells 
(Figure 10, L and M) demonstrated myogenic differentiation in 
some cells. Injections of shRNA-Cdkn2a plus H-RasG12V MuLE 
viruses in C57BL/6 mice and Balb/c mice caused the develop-
ment of sarcomas with kinetics and histology similar to those 
arising in SCID/beige mice (Supplemental Figure 8, A–C), dem-
onstrating that MuLE viruses can also be employed to generate 
autochthonous tumors in immunocompetent mice. Independent 
cell lines were generated from multiple shRNA-Cdkn2a plus 
H-RasG12V, shRNA-Trp53 plus H-RasG12V, and shRNA-Trp53 plus 
shRNA-Pten plus H-RasG12V tumors. Western blotting confirmed 
H-RasG12V overexpression and reduction in protein abundance 
of p16, p19, p53, and PTEN in the respective genotypes (Figure 
10O). While Pten knockdown led to clear induction of Akt phos-
phorylation at S473, no biological differences could be observed 
between tumors or cell lines with or without Pten knockdown. 
Tumor xenografts of these cell lines grew at similar rates (Sup-
plemental Figure 8, D and E) and exhibited histologies indistin-
guishable from the original tumors (Supplemental Figure 8, F–H). 
These findings demonstrate that the MuLE system represents a 
powerful tool allowing the rapid and systematic generation of 
genetically complex, quantitatively monitorable autochthonous 
tumors and tumor-derived cancer cell lines in mice.
Table 1. Genotyping sequencing analysis of mutations at the Pten, Trp53, and Vhl loci in the indicated cell clones
Clone Pten exon 2 Trp53 exon 7 Vhl exon 1
WT CTTGAAGGTGTATACAGGAACAATATT AGCTCCTGCATGGGGGGCATGAACCGC GGGCGGCCGCGGCCGGTGCTGCGCTCG
7 CTTGAAGGTGTAATACAGGAACAATATT 
CTTGAAGGTG.TACAGGAACAATATT
....27bp del.....CATGAACCGC 
AGCTCCTGCATTGGGGGGCATGAACCGC
GGGCGGCC......GGTGCTGCGCTCG 
GGGCGGCCGCCGGCCGGTGCTGCGCTCG
8 CTTGAAGGT....ACAGGAACAATATT 
CTTGAAGGTGT.ACAGGAACAATATT
.........57bp del.......... 
AGCTCC....TGGGGGGCATGAACCGC
GGGCGGCCGCGGC.GGTGCTGCGCTCG 
GGGCGGCCGCGGCCGGTGCTGCGCTCG
9 CTTGAAGGTG....24 bp del..... 
CTTGAAGGTGTAAATACAGGAACAATATT
AGCTCCTGCAATGGGGGGCATGAACCGC 
AGCTCCTGC.TGGGGGGCATGAACCGC
GGGCGGCCGCGGC......TGCGCTCG 
GGGCGGCCG......GTGCTGCGCTCG
10 CTTGA..........AGGAACAATATT 
CTTGAAGGTGT.ACAGGAACAATATT
A...............GCATGAACCGC 
AGCTCCTGCAATGGGGGGCATGAACCGC
GGGCGGCCGC...CGGTGCTGCGCTCG 
GGGCGGCCGCGG.CGGTGCTGCGCTCG
14 CTTGAAGGTGTAATACAGGAACAATATT 
CTTGAAGGTGTATTACAGGAACAATATT
AGCTCCTGCAATGGGGGGCATGAACCGC 
AGCTCCTGCAATTTCC 136 bp ins
GGGCGGCCGCG......GCTGCGCTCG 
GGGCGGCCGCGGCCGGTGCTGCGCTCG
15 CTTGA..........AGGAACAATATT 
CTTGAAGGTGTATTTACAGGAACAATATT
AGCTCCTGCAT.GGGGGCATGAACCGC 
AGCTCCTGCAATGGGGGGCATGAACCGC
GGGCGGCCGCG......GCTGCGCTCG 
GGGCGGCCGCGGC.GGTGCTGCGCTCG
17 CTTGAAGGTGTATTACAGGAACAATATT 
CTTGAAGGTGTATACAGGAACAATATT
AGCTCCTGCAATGGGGGGCATGAACCGC 
AGCTCCTGCAATGGGGGGCATGAACCGC
GGGCGGCCGCG......GCTGCGCTCG 
GGGCGGCCGCGGC.GGTGCTGCGCTCG
18 .........32bp del.......... 
CTTGAAGGTGTAATACAGGAACAATATT
AGCTC...CATGGGGGGCATGAACCGC 
AGCTCCTGC.TGGGGGGCATGAACCGC
GGGCGGCCGCGGC.GGTGCTGCGCTCG 
GGGCGGCCGCG......GCTGCGCTCG
19 C..............AGGAACAATATT 
CTTGAAGGTG............ATATT
AGCTCCTGCAATGGGGGGCATGAACCGC 
AGCTCCTGCAATGGGGGGCATGAACCGC
GG....................GCTCG 
GGGCGGCCGCGGCCGGTGCTGCGCTCG
20 CTTGAAGGTG............ATATT 
CTTGAAGGTGTAAATACAGGAACAATATT
12bp del.ATGGGGGGCATGAACCGC 
AGCTCCTGCAATGGGGGGCATGAACCGC
GGGCGGCC...GCCGGTGCTGCGCTCG 
GGGCGGCCGCGGCCGGTGCTGCGCTCG
The sequences of the 2 alleles of each locus are listed; underlined dots represent a base deletion and underlined text a base insertion compared with the 
WT sequence.
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own experiments using repeated U6 promoter elements showed 
efficient knockdown or CRISPR/Cas9-mediated knockout of all 
genes that were targeted by the shRNAs or sgRNAs, suggesting 
that high levels of recombined viruses are not being produced in 
a manner that negatively affects achieving the desired genetic 
modulations. Another theoretical drawback of lentiviral vectors 
is the potential for insertional mutagenesis, although new gen-
eration HIV-based self-inactivating (SIN) lentiviral vectors (such 
as the vector that the MuLE system is based on) appear to not 
suffer from the problems of deleterious insertional mutagenesis 
that were observed with initial γ-retroviral gene-delivery vectors. 
reverse transcription of the viral genome. Some studies have 
described that repeated genetic elements can undergo recombi-
nation-mediated deletion at low frequency in viral infections (39, 
40), while other studies show that recombination of repeated ele-
ments was not detectable (41, 42). For this reason, we sought to 
provide options that would allow users to avoid the use of repeat-
ed elements in MuLE vectors in the unlikely event that unwanted 
recombination would prove to be an experimental problem. We 
generated Entry vectors with multiple different pol II and pol III 
promoters to allow gene and shRNA expression without incorpo-
rating repeated elements into final MuLE expression vectors. Our 
Figure 9. Combinatorial genetic screening using MuLE vectors. (A) Schematic representation of the workflow to generate a MuLE Entry vector shRNA 
library targeting the listed genes (shRNA X) and the final tricistronic lentiviral expression vector library that was used to screen for shRNAs that cause 
cell transformation in cooperation with oncogenic H-RasG12V overexpression. (B) Quantification of foci that were formed when WT MEFs were transduced 
with the indicted lentiviruses (MOI = 0.1). (C) Western blot analysis of EGFP-expressing cell clones derived from foci harboring shRNA against the indicated 
gene. (D) In vivo fluorescence images of mice that were subcutaneously injected with WT MEFs that had been infected with a MuLE virus expressing the 
identified shRNA against Cdkn2a alone plus iRFP or in combination with H-RasG12V and iRFP. (E) Tumor growth in the same mice monitored by longitudinal 
in vivo fluorescence imaging. All graphs depict mean ± SD. Student’s t test, n = 3. **P < 0.01; ***P < 0.001.
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the phenotype of these tumors. It is noteworthy that Trp53/Pten 
double-knockdown or Pten knockdown plus H-RasG12V expression 
did not lead to tumor formation. These observations are poten-
tially consistent with a recent report that activating PIK3CA and 
inactivating PTEN mutations in embryonal RMS mostly occur 
concurrently with mutations in MYOD1 that functionally block 
myogenic differentiation (46). Thus, in muscle-derived sarcomas, 
the RAS and PI3K pathways appear to cooperate with different sets 
of genes to cause tumor formation.
The fact that MuLE-derived tumors are marked with lucifer-
ase and arise within weeks with uniform kinetics in every mouse 
will be advantageous for preclinical therapeutic studies, as tumor 
burden is quantitatively monitorable using a simple live-animal-
imaging approach. In comparison, the generation of similar 
models using conventional genetic approaches would require the 
interbreeding of at least 4 to 5 different germline-modified trans-
genic mice (for example, tissue-specific Cre expression; homo-
zygous floxed Cdkn2a, Trp53, and/or Pten alleles; Cre-inducible 
alleles of oncogenic H-RasG12V; and luciferase). The flexibility and 
speed of cloning that the MuLE system allows also paves the way 
for a systematic approach to model sarcomas by introducing oth-
er combinations of genetic alterations that occur in these tumor 
types, without the need for extensive crossing of germline-mod-
ified mice. By generating autochthonous tumors via direct injec-
tion of MuLE viruses into existing genetically modified mouse 
strains, it should also be possible to rapidly test, for example, 
the role of potential genetic modifiers or the immune system in 
tumor progression.
Lentiviral vectors allow gene transfer into dividing and 
nondividing cells and are increasingly being used for somatic 
cell transgenesis, including oncogene delivery (25, 47–49). The 
most common envelope protein used for pseudotyping lentivi-
ral vectors is from vesicular stomatitis virus (VSV-G) and allows 
the infection of human cells (50, 51). Here, we have presented 
numerous examples of tumor engineering using the MuLE sys-
tem, employing an ecotropic envelope protein from the Moloney 
murine leukemia virus (7, 52), which offers significant biosafety 
advantages (8). To the best of our knowledge, this envelope pro-
tein has not been previously employed for lentiviral delivery in 
vivo. In the context of tumor modeling in mice using lentiviral 
vectors that are potentially oncogenic in humans, the use of an 
ecotropic envelope prevents possible infection of researchers and 
also allows the use of conventional biosafety level 1 cell-culture 
and animal housing facilities, making this system available to 
almost all research groups. Our preliminary ex vivo and in vivo 
studies indicate that ecotropic MuLE viruses are able to trans-
duce a wide variety of cell types, suggesting wide applicability of 
this system. Given the broad tropism of ecotropic MuLE viruses, 
achieving restricted infection of a particular cell type in vivo via a 
simple injection may not be possible in some settings. Our proof-
of-principle demonstration that cell-type–specific expression 
can be achieved using a kidney-specific promoter element in the 
MuLE system may provide a solution to this issue. We also envis-
age that existing tissue-specific and/or inducible Cre, rtTA, and 
tTA mouse lines could provide the opportunity to spatially and 
temporally restrict gene expression from MuLE vectors contain-
ing loxP sites or tetracycline-responsive elements.
Lentiviral vectors have been shown to be safe in recent gene ther-
apy trials (43, 44). Several lines of evidence demonstrate that ran-
dom insertional mutagenesis of MuLE vectors does not contrib-
ute to the observed phenotypes in this study. Every experiment 
included all control vectors, including vectors with empty inserts, 
or expressing only single or double combinations of genes to con-
trol for potential effects of insertional mutagenesis. For exam-
ple, as shown in Figure 4, E and F, cellular transformation and 
anchorage-independent growth only occurred when Trp53 was 
knocked down together with H-RasG12V overexpression. Cells that 
were infected with MuLE viruses expressing only shRNA-Trp53 
or only H-RasG12V represent genetically sensitized cells that could 
be envisaged as being prone to oncogenic transformation by 
insertional mutagenesis. However, transformed cells that could 
grow in soft agar were never observed in these infections. Simi-
larly, in all of the sarcoma tumor–modeling experiments, none of 
the relevant empty, single, and double control vectors induced 
tumors. Tumors arose rapidly in 100% of mice after injection of 
the shRNA-Cdkn2a plus H-RasG12V, shRNA-Trp53 plus H-RasG12V, 
and shRNA-Trp53 plus shRNA-Pten plus H-RasG12V combinato-
rial MuLE viruses with almost uniform kinetics, indicating that 
the tumors are driven by the genetic alterations introduced by 
the MuLE viruses and not as a result of rare random cooperating 
mutagenic events. One real practical limitation to the complexity 
of cloned MuLE vectors is that, as with all lentiviruses, viral titer 
decreases proportionally to the size of the provirus (Supplemen-
tal Figure 2 and ref. 45). In our hands, proviruses up to approxi-
mately 12 kb were able to generate experimentally usable viral 
titers; however, users are advised to generate the smallest pos-
sible proviruses if achieving a very high viral titer is experimen-
tally important. The MuLE Entry vector toolbox is theoretically 
also compatible with other Gateway cloning–based plasmid and 
viral delivery systems, potentially allowing for larger and more 
complicated vectors and providing additional opportunities for 
targeting different cell types.
A great promise of the MuLE system is the potential to allow 
genetic manipulation of somatic cells directly in mice and poten-
tially in other mammals. Bypassing extensive germline transgenic 
approaches has major benefits in terms of time and cost, and the 
lentiviral-mediated somatic genetics approach also mimics the 
fact that many cancer-associated genetic alterations are acquired 
in somatic cells. In this context, by engineering 3 new autoch-
thonous mouse models of sarcoma, we show that MuLE viruses 
can be used to systematically assess the contribution of tumor 
suppressors and oncogenes to tumor formation in vivo. We show 
that the combinations of oncogenic H-RasG12V expression plus 
knockdown of Cdkn2a, Trp53, or both Trp53 and Pten cause the 
formation of undifferentiated sarcomas with pleomorphic and 
rhabdoid features from skeletal muscles in mice. The histologi-
cal similarity of these tumor models to existing transgenic mouse 
muscle–derived sarcoma models that are driven by oncogenic 
K-RasG12V in Trp53 null, Trp53 point mutant, or Cdkn2a null genetic 
backgrounds (27–30) demonstrates that MuLE viruses can be 
employed to recapitulate transgenic tumor models. Interestingly, 
additional Pten knockdown in shRNA-Trp53 plus H-RasG12V tumors 
caused phosphorylation of AKT, demonstrating hyperactivation of 
the PI3K pathway, but did not lead to any obvious differences in 
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Cloning of sgRNAs, surveyor assays, and next generation sequenc-
ing. Design and cloning of sgRNAs used in this study are described in 
Supplemental Methods. For Surveyor assays, 350- to 450-bp fragments 
surrounding the sgRNA target site were amplified using proof-reading 
PCR (Expand High Fidelity, Roche). Primers and PCR conditions are 
described in Supplemental Methods. For mixed cell populations, hetero-
duplexes were formed by reannealing the PCR product alone by heating 
to 95°C followed by gradual cooling. Heteroduplexes were digested with 
Surveyor nuclease (7 μl heteroduplex, 1 μl Surveyor Enhancer S, 1 μl Sur-
veyor Nuclease S, 1 μl 0.15 M MgCl2) for 60 minutes at 42°C and subjected 
to 10% polyacrylamide gel electrophoresis using 1× TBE as running buf-
fer. For sequencing of the Trp53, Vhl, and Pten loci in cell clones, gene seg-
ments surrounding the sgRNA-binding site were amplified from genomic 
DNA using primers described in Supplemental Methods, followed by liga-
tion to barcoded adaptors and pooled sequencing using Ion Torrent PGM. 
The full protocol is provided in Supplemental Methods. Sequencing data 
were deposited in the NCBI’s BioProject database (ID 272478).
Lentivirus production and titration. Lentivirus was prepared using 
calcium phosphate-mediated transfection of subconfluent HEK293T 
cells cultured in DMEM plus 10% FCS. For a 10-cm dish, lentiviral 
vector (8 μg) was cotransfected with the lentiviral packaging vec-
tor psPAX2 (Addgene, no. 12260) and either the ecotropic envelope 
(pCMV-Eco, Cellbiolabs, no. RV-112) or the amphotropic envelope 
(pMD2.G, Addgene, no. 12259). Concentration of lentiviral par-
ticles for in vivo injection was done via centrifugation for 5 hours at 
11,000 g over a layer of 20% sucrose (55). In cases in which the viral 
construct contained a drug-resistance gene, determination of func-
tional viral titer was performed by drug-resistance colony assay with 
NIH3T3 cells as described (56). In cases in which fluorescent reporters 
expressed from the constructs, titers were determined using FACS as 
described (56). For determination of titers with luciferase as the only 
reporter, we generated an EGFP-luciferase–expressing lentiviral vec-
tor and used this to generate a reference curve, which allowed us to 
determine the titer of viruses by measuring luciferase activity in cells 
that had been transduced with different dilutions of the virus.
Antibodies, Western blotting, and immunohistochemistry. Western 
blotting and immunohistochemistry were conducted as described (57) 
using antibodies against the following epitopes: H-Ras (Santa Cruz Bio-
technology Inc., no. sc-520), β-actin (Sigma-Aldrich, A2228), p16 (Santa 
Cruz Biotechnology Inc., no. sc-1207), p19 (Santa Cruz Biotechnology 
Inc., no. sc-32748), Myc (Sigma-Aldrich, no. M5546), VHL (Santa Cruz 
Biotechnology Inc., sc-5575), p53 (Novocastra, NCL-p53-CM5p), PTEN 
(Santa Cruz Biotechnology Inc., no. sc-7974), GFP (Life Technologies, 
no. G10362), Rb1 (Cell Signaling, no. 9313), HIF1α (Novus, no. NB100-
479), p21 (F5) (no. sc-6246), phospho-Akt (Ser473) (193H12) (Cell Sig-
naling, no. 4058), and Akt (pan) (C67E7) (Cell Signaling no. 4691). The 
full scans of all Western blots are available in the Supplemental Material.
Real-time PCR. Real-time PCR was performed as described (57) 
using the following primer pairs: S12 (5′-GAAGCTGCCAAAGCCT-
TAGA-3′, 5′-AACTGCAACCAACCACCTTC-3′), Hif1a (5′-TGCT-
CATCAGTTGCCACTTC-3′, 5′-CCTCATGGTCACATGGATGA-3′), 
Hif2a (5′-GAGGAAGGAGAAATCCCGTGA-3′, 5′-CTGATGGCCAGG 
CGCATGATG-3′), Vegfa (5′-CTTGTTCAGAGCGGAGAAAGC-3′, 
5′-ACATCTGCAAGTACGTTCATT-3′), Pdk1 (5′-GGACTTCGGGT-
CAGTGAATGC-3′, 5′-TCCTGAGAAGATTGTCGGGGA-3′), and 
Pgk1 (5′-TGCTGCTGAACTCAAATCTCTG-3′, 5′-CAGGCATTCTC-
GACTTCTGGG-3′).
Methods
Cells. Primary MEFs were isolated from relevant WT or floxed strains 
and were frozen in aliquots at passage 2. MEFs were cultured in 
DMEM plus 10% FCS in cell-culture incubators supplemented with 
5% CO2 and maintained at 5% O2. If not stated otherwise, cells were 
transduced at a MOI between 1 and 2. MEFs were incubated overnight 
in virus-containing medium in the presence of 4 μg/ml polybrene (Sig-
ma-Aldrich, no. H9268). Drug selection was performed 48 hours after 
transduction using the following concentrations: 3 μg/ml puromycin, 
10 μg/ml blasticidin, 500 μg/ml G418. Human melanoma A-375 cells 
(ATCC, no. CRL-1619) were cultured in DMEM plus 10% FCS. C2C12 
cells were obtained from Sigma-Aldrich (no. 91031101) and cultured in 
DMEM plus 15% FCS. HEK293T (ATCC, no. CRL3216) and NIH3T3 
cells (ATCC, no. CRL-1658) were cultured in DMEM plus 10% FCS. 
LLC-1, B16-F10, and MC-38 cell lines were a gift of Lubor Borsig 
(Institute of Physiology, University of Zurich) and cultured in DMEM 
plus 10% FCS. Mouse embryonic stem cells were a gift of Kurt Bürki 
(Institute of Physiology, University of Zurich) and cultured in N2B27+ 
2i medium. Murine primary kidney epithelial cells were isolated and 
cultured as described before (53). Endometrial epithelial cells were 
isolated and cultured as described (54). Murine aortic endothelial 
cells and immortalized mouse hepatocytes were gifts of Rok Humar 
(Research Unit, Division of Internal Medicine, University Hospital of 
Zurich, Zurich, Switzerland) and Nora Rösch (Institute of Molecular 
Health Sciences, ETH Zurich, Zurich, Switzerland), respectively, and 
were cultured in DMEM plus 10% FCS. Cells were isolated from dis-
sected tumors by digestion for 1 hour at 37°C with 1 mg/ml collage-
nase type II (Gibco; Life Technologies), washed twice with PBS, and 
cultured in DMEM plus 10% FCS. All cells were kept in cell-culture 
incubators supplemented with 5% CO2 and maintained at 20% O2.
Cloning of MuLE vectors. Details of the cloning of all parental 
MuLE Entry and Destination vectors, the experimental Entry vec-
tors, and experimental MuLE expression vectors that were used in this 
study are provided in Supplemental Methods.
Figure 10. Generation of 3 autochthonous mouse models of undif-
ferentiated sarcoma using MuLE vectors. (A) Intramuscular injection 
of ROSA26-lox-STOP-lox-tdTomato mice with control or Cre-expressing 
virus. Bottom left panel shows infected myofibers, and small cells adja-
cent to myofibers are seen at higher magnification (arrowheads, bottom 
right panel). (B) Bioluminescence imaging 3 and 31 days after injection 
of 3 × 105 functional viral particles into each gastrocnemius muscle of 
18-day-old SCID/beige mice with MuLE-luciferase viruses expressing 
combinations of shRNA against Cdkn2a, Trp53, and Pten with or without 
expression of H-RasG12V. (C) Quantification (mean ± SD) of luminescent 
signal intensities over time after injection. †Sacrifice of all mice in these 
cohorts by this time point. (D) A tumor (arrow) in a mouse injected with 
the shCdkn2a plus H-RasG12V MuLE virus only in the right gastrocnemius 
muscle. (E) Histological image of the tumor (T) from D surrounded by 
muscle tissue (M). (F–K) Representative histology of tumors derived from 
injection of shCdkn2a plus H-RasG12V (F and G), shTrp53 plus H-RasG12V 
(H and I), and shTrp53 plus shPTEN plus H-RasG12V (J and K) viruses. 
Arrowheads in G, I, and K highlight pleomorphic rhabdoid cells. (L) EM 
showing an example of a tumor cell with sarcomere formation; M and N 
show higher magnification of the regions in L marked with an arrowhead 
and arrows, respectively, showing Z-bands or irregular masses of Z-band 
material with converging filaments. (O) Western blot analysis of indepen-
dent cell lines (lanes 1–8) derived from independent tumors of the indi-
cated genotypes. MEFs, muscle tissue, and C2C12 myoblast cells served as 
controls. Scale bars: 50 μm (A and F–K); 10 μm (L); 500 nm (M and N).
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